Abstract
Objective To collect and analyze the clinical feature of triple-negative breast cancer (TNBC) in Beijing, to provide the information for the local oncologist to make sound treatment plans.
Method The clinical data of 280 breast cancer patients with TNBC admitted to the oncology hospital of China Academy of Medical Sciences were collected and divided into (recurrence and metastasis) group and non-(recurrence and metastasis) group. Breast cancer patients with TNBC were classified according to age distribution, family history of breast cancer, pathological type, histological grade, clinical stage, tumor thrombus, tumor size and lymph node metastasis. and 15 BRCA1 gene SNP loci were also measured by a high throughput Mass ARRAY time-of-flight mass spectrometry biochip system and compared the expression of 15 BRCA1 gene SNP loci between (recurrence and metastasis) group and non-(recurrence and metastasis) group. χ2 test was used to analyze the difference between two groups, and P<0.05 considered statistically significant.
Results A total of 280 breast cancer patients with TNBC were enrolled in this study, median age 45 years old. There were 117 cases breast cancer patients with TNBC in (recurrence and metastasis) group, accounting for 41.79% in total breast cancer patients with TNBC and 163 cases breast cancer patients with TNBC in non-(recurrence and metastasis) group, accounting for 58.21% in total breast cancer patients with TNBC; There was no significant difference in age distribution, family history of breast cancer, pathological type and histological grade between non-(recurrence and metastasis) group and (recurrence and metastasis) group (P>0.05); but there were significant differences in clinical stage, vascular tumor thrombus, tumor size and lymph node metastasis between two groups (P<0.05); and then we compared the expression of 15 BRCA1 gene SNP loci in (recurrence and metastasis) group and non-(recurrence and metastasis) group, found that BRCA1gene rs 12516 CC loci (38.8% VS 44.4%), BRCA1gene rs 12516 TT loci (15.6% VS 10.4%), BRCA1 gene rs 16940 CC loci (15.1% VS 10.4%), BRCA1 gene rs 16940 TT loci (39.0% VS 44.8%), BRCA1 gene rs 16941 AA loci (38.1% VS 44%), BRCA1 gene rs 16941 GG loci (15.0% VS 10.3%), BRCA1 gene rs16942 AA loci (39.0% VS 44.8%), BRCA1 gene rs16942 GG loci (15.1% VS 10.4%), BRCA1gene rs799906 CC loci (15.9% VS 10.4%), BRCA1gene rs799906 TT loci (38.7% VS 44.8%), BRCA1gene rs799917 CC loci (38.7% VS 44.4%), BRCA1gene rs799917 TT loci (15.7% VS 10.4%), BRCA1gene rs1060915 CC loci (15.5% VS 10.4%), BRCA1gene rs1060915 TT loci (39.1%VS 44.8%), BRCA1gene rs1799966 AA loci (37.7% VS 44.4%), BRCA1gene rs1799966 GG loci (15.1% VS 10.4%), BRCA1 Gene rs2070833 AA loci (3.1% VS 7.0%), BRCA1 Gene rs2070833 CC loci (56.3% VS 51.3%), BRCA1gene rs3737559 GG loci(78.5% VS 84.5%), BRCA1gene rs3737559 GA loci(19.0% VS 14.6%), BRCA1gene rs8176199 AA loci (60.5% VS 64.6%), BRCA1gene rs8176318 GG loci (38.4% VS 43.4%), BRCA1gene rs8176318 TT loci (15.1% VS 10.6%), BRCA1gene rs8176323 CC loci (38.6% VS 43.9%), BRCA1gene rs8176323 GG loci (15.2% VS10.5%), BRCA1gene rs11655505 AA loci (14.9% VS 10.4%), BRCA1gene rs11655505 GG loci (39.1% VS 44.8%) had a difference at the accident rate between recurrence and metastasis group and non-(recurrence and metastasis) group, but the frequencies of genotypes in the (recurrence and metastasis) group and non-(recurrence and metastasis) group were similar, there was no statistical significant correlation between the SNP genotype of the BRCA1 gene and the recurrence and metastasis risk of TNBC (P>0.05).
Conclusions There were higher recurrence and metastasis (41.79%) in total 280 cases breast cancer patients with TNBC in Beijing area; breast cancer patients with TNBC in Beijing area had a unique clinical feature no matter at clinical stage, vascular tumor thrombus, tumor size and lymph node metastasis or the expression of 15 BRCA1 gene SNP loci, those data may provide some information for clinical staff for TBNC treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I have the right to post this manuscript and confirm that all authors have assented to posting of the manuscript. All relevant ethical guidelines have been followed. Details of the oversight body: Ethics committee of Xinxiang Central Hospital(the Fourth Clinical College of Xinxiang Medical University) suggested that The clinical feature of triple-negative breast cancer in Beijing, China is ethical in according with Ethics committee of Xinxiang Central Hospital(the Fourth Clinical College of Xinxiang Medical University), and agree to conduct relevant experiments. All necessary patient/participant consent has been obtained. I am legally responsible for the content of the article. I have followed all appropriate research reporting guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.
